论文部分内容阅读
目的：比较研究阿克他利治疗类风湿关节炎的疗效和安全性。方法：随机、双盲比较研究。共完成病例１３５例，试验组６７例，口服阿克他利１００ｍｇ，每天三次；对照组６８例，口服甲氨喋呤（ＭＴＸ） １０ ｍｇ，每周一次，疗程１２周。结果：治疗６周、１２周后，总有效率：ＡＣＴ组为３５．８２％，６２．６９％；ＭＴＸ组为４５．５９％，７２．０６％（Ｐ＜０．０５）。两药均能明显改善患者的症状和体征，１２周时能降低血沉，Ｃ－反应蛋白和类风湿因子水平。ＭＴＸ在改善患者的休息痛、关节压痛数及压痛指数、双手握力、医师评价、病人评价及降低血沉方面优于ＡＣＴ（Ｐ＜０．０５）。安全性评价：药物不良反应发生率：ＡＣＴ组８．９６％（６／６７）ＭＴＸ组２３．５３％（１６／６８），ＡＣＴ的耐受性优于ＭＴＸ（Ｐ＜０．０５）。结论：阿克他利是一个安全性好且较有效的治疗类风湿关节炎的新型抗风湿药。
OBJECTIVE: To compare the efficacy and safety of acterex in the treatment of rheumatoid arthritis. Methods: Randomized, double-blind comparative study. A total of 135 cases were completed, the experimental group of 67 patients, oral acetalipat 100mg, three times a day; the control group of 68 patients, oral methotrexate (MTX) 10 mg once a week for 12 weeks. Results: After 6 weeks and 12 weeks of treatment, the total effective rate was 35.82% and 62.69% respectively in ACT group and 45.59% and 72.06% in MTX group (P <0.05). Both drugs can significantly improve the patient’s symptoms and signs, 12 weeks can reduce the erythrocyte sedimentation rate, C-reactive protein and rheumatoid factor levels. MTX was superior to ACT in improving resting pain, joint tenderness and tenderness index, handshake, physician evaluation, patient evaluation, and hematopoietic reduction (P <0.05). Safety evaluation: The incidence of adverse drug reactions: ACT group 8.96% (6/67) MTX group 23.53% (16/68), ACT was better than MTX tolerance (P <0.05). Conclusion: Acetari is a safe and effective antirheumatic drug for the treatment of rheumatoid arthritis.